Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Descrición completa

Detalles Bibliográficos

Principais autores:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2025-07-01
Series:	BMC Cancer
Assuntos:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
Acceso en liña:	https://doi.org/10.1186/s12885-025-14400-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!